drugset / Trial / NCT05705024

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024

RandomizedParallel-groupDouble-blindTreatment

Summary

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

Timeline

Start
2023-09-29
Primary completion
2026-09-28
Completion
2026-09-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator mesenchymal stem cells Cell therapy 3e+06 cells Other

Indications